Taletrectinib for ROS1+ lung cancer with brain spread
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced lung cancer (stage 4) that has spread to other parts of your body.
- Your cancer has a specific change called ROS1 gene fusion, confirmed by a standard lab test.
- You have at least one brain tumor that can be measured on a scan, and any brain symptoms have been stable for the past 2 weeks.
- Your doctor believes the study drug (taletrectinib) could help you, OR you have already taken taletrectinib for 6 months or less.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study looks at how well a targeted therapy works for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests a combination of a targeted therapy (firmanertinib), a biologic drug that blocks blood vessel growth (bevacizumab), and a chemotherapy given into the spinal fluid (pemetrexed) for people with non-small cell lung cancer that has spread to the membranes around the brain (leptomeningeal metastasis). The goal is to see if this treatment helps control the cancer and improve symptoms.
This trial studies a new drug called sacituzumab tirumotecan combined with brain radiation for people with EGFR-positive lung cancer that has spread to the brain and has grown despite targeted therapy. The goal is to see if this combination can better control the brain tumors.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.